In conclusion, our study identifies WFDC3 as a pro-oncogenic factor in PAAD progression, highlighting its potential as both a prognostic biomarker and a therapeutic target for regulating metastasis and immune responses in this malignancy. The gene discussed is WFDC3; the disease is pancreatic adenocarcinoma.